Skip to Content
Merck
  • Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.

Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.

Oncoimmunology (2015-09-26)
Wendy Wj Unger, Christian T Mayer, Steef Engels, Christina Hesse, Maurizio Perdicchio, Franz Puttur, Ingeborg Streng-Ouwehand, Manja Litjens, Hakan Kalay, Luciana Berod, Tim Sparwasser, Yvette van Kooyk
PMID26405564
ABSTRACT

Therapeutic vaccinations against cancer are still largely ineffective. Major caveats are inefficient delivery of tumor antigens to dendritic cells (DCs) and excessive immune suppression by

MATERIALS
Product Number
Brand
Product Description
B5936
Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, Ready Made Solution, 10 mg/mL in DMSO
E2028
Sigma-Aldrich
Ethidium bromide monoazide, ≥95% (HPLC), solid
W292907
Sigma-Aldrich
Isopropyl alcohol, ≥99.7%, FCC, FG
79346
Sigma-Aldrich
Phorbol 12-myristate 13-acetate, synthetic, ≥98.0% (TLC)
B6542
Sigma-Aldrich
Brefeldin A, ≥99% (HPLC and TLC), BioXtra, for molecular biology
P1585
Sigma-Aldrich
PMA, for use in molecular biology applications, ≥99% (HPLC)
278475
Sigma-Aldrich
2-Propanol, anhydrous, 99.5%
D9542
Sigma-Aldrich
DAPI, for nucleic acid staining
I9516
Sigma-Aldrich
2-Propanol, for molecular biology, BioReagent, ≥99.5%
59304
Sigma-Aldrich
2-Propanol, BioUltra, for molecular biology, ≥99.5% (GC)
437522
Sigma-Aldrich
2-Propanol, ACS reagent, ≥99.5%
733458
Sigma-Aldrich
2-Propanol, electronic grade, 99.999% trace metals basis